Long term response in a patient with neoplastic meningitis secondary to melanoma treated with131I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab?)2

Cokgor, Ilkcan; Akabani, Gamal; Friedman, Henry S.; Friedman, Allan H.; Zalutsky, Michael R.; Zehngebot, Lee M.; Provenzale, James M.; Guy, Cynthia D.; Wikstrand, Carol J.; Bigner, Darell D.

doi:10.1002/1097-0142(20010501)91:9<1809::aid-cncr1200>3.0.co;2-l

Cited by 30 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group also reported a long term response in a patient with a neoplastic meningitis that developed secondary to malignant melanoma when the patient was treated with intrathecal 131 I-labeled Mel-14 F(ab 0 ) 2 (253). Neoplastic meningitis typically represents a terminal stage of malignant melanoma.…”

Section: Passive Antibody Treatmentmentioning

confidence: 82%

Immunotherapy of malignant brain tumors

Mitchell¹,

Fecci

Sampson

2008

Immunological Reviews

View full text Add to dashboard Cite

SummaryDespite aggressive multi-modality therapy including surgery, radiation, and chemotherapy, the prognosis for patients with malignant primary brain tumors remains very poor. Moreover, the nonspecific nature of conventional therapy for brain tumors often results in incapacitating damage to surrounding normal brain and systemic tissues. Thus, there is an urgent need for the development of therapeutic strategies that precisely target tumor cells while minimizing collateral damage to neighboring eloquent cerebral cortex. The rationale for using the immune system to target brain tumors is based on the premise that the inherent specificity of immunologic reactivity could meet the clear need for more specific and precise therapy. The success of this modality is dependent on our ability to understand the mechanisms of immune regulation within the central nervous system (CNS), as well as counter the broad defects in host cell-mediated immunity that malignant gliomas are known to elicit. Recent advances in our understanding of tumor-induced and host-mediated immunosuppressive mechanisms, the development of effective strategies to combat these suppressive effects, and a better understanding of how to deliver immunologic effector molecules more efficiently to CNS tumors have all facilitated significant progress toward the realization of true clinical benefit from immunotherapeutic treatment of malignant gliomas.

show abstract

Section: Passive Antibody Treatmentmentioning

confidence: 82%

Immunotherapy of malignant brain tumors

Mitchell¹,

Fecci

Sampson

2008

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…Transduction inhibitors,[6133476] agents targeting angiogenesis (angiostatin)[232] or vascular cell adhesion molecules[29] are currently under investigation.…”

Section: New Therapeutic Approachesmentioning

confidence: 99%

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors

Rhun

Taillibert²,

Mc³

2013

Surg Neurol Int

223

143

View full text Add to dashboard Cite

Leptomeningeal metastasis (LM) results from metastatic spread of cancer to the leptomeninges, giving rise to central nervous system dysfunction. Breast cancer, lung cancer, and melanoma are the most frequent causes of LM among solid tumors in adults. An early diagnosis of LM, before fixed neurologic deficits are manifest, permits earlier and potentially more effective treatment, thus leading to a better quality of life in patients so affected. Apart from a clinical suspicion of LM, diagnosis is dependent upon demonstration of cancer in cerebrospinal fluid (CSF) or radiographic manifestations as revealed by neuraxis imaging. Potentially of use, though not commonly employed, today are use of biomarkers and protein profiling in the CSF. Symptomatic treatment is directed at pain including headache, nausea, and vomiting, whereas more specific LM-directed therapies include intra-CSF chemotherapy, systemic chemotherapy, and site-specific radiotherapy. A special emphasis in the review discusses novel agents including targeted therapies, that may be promising in the future management of LM. These new therapies include anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib in nonsmall cell lung cancer, anti-HER2 monoclonal antibody trastuzumab in breast cancer, anti-CTLA4 ipilimumab and anti-BRAF tyrosine kinase inhibitors such as vermurafenib in melanoma, and the antivascular endothelial growth factor monoclonal antibody bevacizumab are currently under investigation in patients with LM. Challenges of managing patients with LM are manifold and include determining the appropriate patients for treatment as well as the optimal route of administration of intra-CSF drug therapy.

show abstract

“…CSPG overexpression in gliomas with the mAb Mel-14 is well documented [45]. Intrathecal administration of 131 I-labeled mAb Mel-14 F(ab′)2 fragment, in a 46-year-old neoplastic meningitis patient, produced a long-term response, with no indication of the disease 4 years post-treatment [46]. …”

Section: Current Immunotherapeutic Approaches Against Malignant Brainmentioning

confidence: 99%

Antibody, T-cell and Dendritic Cell Immunotherapy for Malignant Brain Tumors

et al. 2013

View full text Add to dashboard Cite

Modest improvement in brain tumor patient survival has been achieved through advances in surgical, adjuvant radiation and chemotherapeutic strategies. However, these traditional approaches have been unsuccessful in permanently controlling these aggressive tumors, with recurrence being quite common. Hence, there is a need for novel therapeutic approaches that specifically target the molecularly diverse brain tumor cell population. The ability of the immune system to recognize altered tumor cells while avoiding surrounding normal cells offers an enormous advantage over the nonspecific nature of the conventional treatment schemes. Therefore, immunotherapy represents a promising approach that may supplement the standard therapies in eliminating the residual brain tumor cells. This review summarizes different immunotherapeutic approaches currently being tested for malignant brain tumor treatment.

show abstract

Long term response in a patient with neoplastic meningitis secondary to melanoma treated with131I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab?)2

Cited by 30 publications

References 16 publications

Immunotherapy of malignant brain tumors

Immunotherapy of malignant brain tumors

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors

Antibody, T-cell and Dendritic Cell Immunotherapy for Malignant Brain Tumors

Contact Info

Product

Resources

About